Acorda Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Acorda Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Acorda Therapeutics Inc Strategy Report
- Understand Acorda Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Acorda Therapeutics Inc (Acorda), is a biopharmaceutical company that specializes in identification, development and marketing of therapies for people with neurological disorders such as Parkinson's disease, multiple sclerosis and other neurological disorders. It operates one reportable segment. The company’s marketed product portfolio consists of Ampyra or Fampyra (dalfampridine), and Inbrija. Its proprietary ARCUS technology is a dry-powder pulmonary drug delivery technology that enables the delivery of medication through inhalation.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Acorda’s R&D efforts focuses on developing novel therapies for the treatment of neurological disorders. Its major pipeline products include rHIgM22 and Cimaglermin alfa. Key proprietary technology includes ARCUS technology. In FY2022, the company spent US$5.8 million on its R&D expenses, which as a percentage of total revenue stood at 4.9%. The company’s patent portfolio comprises US and foreign patents related to Inbrija and the ARCUS drug delivery technology and one European patents for dalfampridine composition.
Business Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Product Categories
Overview
- Is an extended-release oral dalfampridine formulation. - Holds the FDA approval as an oral drug administered for improving walking in people with MS. - Acorda commercializes Ampyra through an agreement with Biogen International GmbH (Biogen) outside the US under the brand name, Fampyra. Fampyra is approved in various countries including Europe, Asia, and the Americas (excluding the US).
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
- Is the only inhaled levodopa (L-dopa) which holds the FDA approval for the intermittent treatment of OFF episodes in people with Parkinson’s disease and on a carbidopa or L-dopa regimen. - It uses the company’s ArCUS platform for inhaled therapeutics - Acorda’s Inbrija received the European Commission Marketing Authorization Application (MAA) as an intermittent treatment for episodic motor fluctuations or OFF episodes in adult patients with Parkinson’s disease and who were previously treated with a dopa-decarboxylase inhibitor or levodopa. The MAA approval also enables the company to market Inbrija in 27 countries in the European Union (EU), Iceland, Liechtenstein, and Norway. - The company sells Inbrija in the US through its own sales force, a network of specialty pharmacies, and through ASD Specialty Healthcare Inc, an affiliate of AmeriSource Bergen.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer